Kyverna Therapeutics Has Been Granted FDA Fast Track Designation for KYV-101 in the Treatment of Patients With Refractory Progressive Multiple Sclerosis
Saturday, January 20, 2024
Kyverna Therapeutics, Inc. (Kyverna) has recently been granted fast track designation by the U.S. Food and Drug Administration (FDA) for its autologous CD19 chimeric antigen receptor (CAR) T-cell product candidate, KYV-101, aimed at treating multiple sclerosis (MS). This designation is part of an FDA program intended to accelerate the development and review of drugs targeting unmet medical needs for serious or life-threatening conditions.
Peter Maag, Ph.D., the CEO of Kyverna, expressed gratitude for the FDA's support in expediting the development of CAR T-cell therapies, emphasizing their potential to significantly benefit patients with severe neurological autoimmune diseases. The fast track designation represents a crucial milestone in Kyverna's efforts to transform the treatment landscape with KYV-101.
CAR T-cell therapy involves modifying a patient's T cells to target and eliminate specific cells, in this case, CD19-expressing B cells associated with autoimmune diseases. Kyverna plans to explore additional indications for KYV-101 and build a comprehensive pipeline of immunotherapies to address unmet medical needs in autoimmune diseases.
Multiple sclerosis is a chronic neurodegenerative autoimmune disease affecting over 2.8 million individuals worldwide, with symptoms ranging from vision problems to severe disability. Existing treatments aim to reduce relapses and delay disability progression, but the disease remains chronic and progressive for most patients.
KYV-101, an autologous, fully human CD19 CAR T-cell product, was developed by the National Institutes of Health (NIH) and underwent a successful Phase 1 trial in oncology. Kyverna is currently conducting trials for KYV-101 in lupus nephritis, with additional trials planned for systemic sclerosis, myasthenia gravis, and multiple sclerosis. The unique properties of KYV-101 are considered crucial for the potential success of CAR T cells in autoimmune disease therapies.
Source: prnewswire.com
